{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 42,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "The slide uses a stacked bar chart to show market share evolution over three quarters and bulleted lists to summarize clinical trial outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/37",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.93,
        "x": 0.035,
        "y": 0.84
      },
      "kind": "callout",
      "text": "DESTINY-Breast03 OS data supports ambition to move earlier line with Enhertu, potentially curative",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e46543a0-fee2-45aa-b272-591c8e440123",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Accelerated adoption in 2L HER2-high",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd311c6d-d6be-4aff-afb2-4bdcfda14443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "DESTINY-Breast04: Launch in HER2-low progressing, Enhertu used in >1/3 HR+ post-chemo population as of Q3 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11b737ca-a0b3-43e8-96fc-008ff23c9c2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "DESTINY-Breast03: OS data shows Enhertu significantly reduced risk of death by 36% (HR 0.64); Rapid adoption in 2L HER2-high patients following approval May 2022 (US); >35% new patient share in Germany and France in first launch quarter",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee63221e-8066-49d7-9f1b-b0fc2851bf48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.035,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Q1'22 data from ZoomRx ENHERTU HER2+ mBC US Quarterly Launch Tracker (PCA)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43b81865-13bb-4797-9c26-c719d0b856ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.035,
        "y": 0.13
      },
      "kind": "title",
      "text": "DESTINY-Breast03 OS data supports Enhertu as market leader in 2L HER2-high",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adc0add1-ac20-4f54-a59c-ee950caecf90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.14,
        "x": 0.035,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44a1a08a-42bf-4c27-825d-071606eacc38",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "43c20784-2918-4a85-bcc0-129e1aa1bbbf",
      "evidence": "The slide uses a clear, thesis-driven headline that summarizes the key takeaway.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 37,
      "from": 30,
      "beatId": "88b7703b-c29f-499c-87c5-dd04e5a0e55a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Other key data, Enhertu, and capivasertib",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}